Hims & Hers Health Guides Q4 Below Estimates After Q3 Revenues Jump 49.2%
Hims & Hers Health posted $599 million in Q3 revenue, up 49.2% year-on-year, and grew its customer base by 32,000 to 2.47 million. Analysts project 28.4% revenue growth in Q4, down from 95.1% last year, after guidance missed expectations and shares slid 46.7% over the past month.
1. Q3 Financial Highlights
In its latest quarter, Hims & Hers Health delivered $599 million in revenue, marking a 49.2% increase year-over-year. The company added 32,000 customers to reach 2.47 million and beat EPS estimates, though it provided cautious commentary on future sales.
2. Q4 Guidance and Analyst Expectations
The company’s guidance for Q4 revenue comes in below consensus, with analysts forecasting 28.4% growth year-over-year compared to a 95.1% surge in the prior-year period. Analyst estimates have remained stable over the past month, reflecting confidence in the core business despite the slowdown.
3. Share Performance and Analyst Price Targets
Hims & Hers shares have fallen 46.7% over the last month as investors weighed the revenue slowdown and conservative outlook. The average analyst price target stands at $27.46, implying significant upside from current levels.
4. Peer Comparisons
In the healthcare technology segment, peers delivered mixed results, with Tandem Diabetes reporting 15% revenue growth and a 32.7% stock surge post-earnings, while Omnicell’s 2.3% revenue increase coincided with a 20.6% share decline. These divergent outcomes highlight investor sensitivity to growth rates and guidance.